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Approximately 9200 cancers of the urinary bladder are registered
in England and Wales each year, of which 6500 in men (8% of all
malignancies) and 2700 in women (3%) (Office for National
Statistics, 2003). Bladder cancer ranks as the fourth most common
in men and ninth in women, and it causes approximately 4300
deaths (2800 in men) a year in England and Wales.
Incidence increases with age, most steeply above the age of 60
years. The two-fold or greater excess in men is world-wide (Ferlay
et al, 2004), and the excess is three-fold above the age of 60 years.
Bladder cancer is uncommon below the age of 50 years, except in
countries where it is linked with chronic schistosomal infestation
of the bladder. Both incidence and mortality show deprivation
gradients, with higher rates in more deprived areas, but the
differences are small (Quinn et al, 2001).
Incidence rose steadily in both sexes during the 1970s and 1980s,
reaching a peak of approximately 31 cases per 100 000 per year in
men and 9 per 100 000 in women by 1990. Incidence has fallen by
approximately 10% since then in both sexes. Annual death rates in
men have fallen by a third since the early 1990s (from 12 to 8 per
100 000), but the death rate in women (3 per 100 000) has not
changed (Quinn et al, 2001).
Most bladder cancers (90%) are urothelial (transitional cell)
carcinomas, often arising on the surface of small papillary tumours.
The remaining 10% comprise mainly squamous cell carcinomas and
adenocarcinomas. European recommendations for coding bladder
tumours changed in 1995 to exclude some urothelial papillary
tumours of the bladder that would previously have been classified as
invasive (Pheby et al, 1995). Similar recommendations were
implemented by UK cancer registries, but only for tumours
registered from 2000 (UK Association of Cancer Registries, 2004).
Tobacco smoking confers a two- to three-fold risk. Occupational
exposure to aromatic amines and polycyclic aromatic hydro-
carbons in the chemical, rubber, transport and dye industries can
also cause bladder cancer. Chemotherapeutic drugs, such as
cyclophosphamide, and therapeutic irradiation of the pelvic region
also increase the risk (Silverman et al, 2006).
Haematuria or pain often leads to the diagnosis. Approximately
75% of tumours are superficial (confined to the bladder mucosa or
submucosal layer without muscle invasion) and these can be treated
by transurethral resection. Tumours that have invaded muscle may
require open surgery and a combination of intravesical or systemic
chemotherapy, immunotherapy and radiotherapy.
Approximately 12% (21 000) of all the bladder tumours
registered in England and Wales during the period 1986–1999
were coded as in situ (behaviour code 2) or uncertain if benign
or malignant (behaviour code 1). The proportion of tumours in
these categories has risen very sharply, from virtually zero during
1986– 1990 (Coleman et al, 1999) to approximately 23% during the
1990s (data not shown). Large regional variations were also seen.
These tumours were considered ab initio as ineligible for inclusion
in the survival analyses.
Of the 160 614 eligible patients with a tumour explicitly coded as
a malignant, invasive (behaviour code 3), primary cancer of the
bladder, some 5% were excluded because their recorded duration
of survival was zero (date of diagnosis same as date of death).
Some of these patients will have been diagnosed on the day of
death, but in many cases the cancer registration was based solely
on the death certificate; hence, the date of diagnosis was unknown.
It was not possible to distinguish these cases reliably in the
available data; hence, all patients with ‘zero survival’ were
excluded. The proportion of patients excluded for this reason
was the same for all deprivation groups (data not shown). Only
patients for whom the bladder cancer was the first primary
malignancy were retained in the analyses; 5% of patients known to
have had a previous primary cancer at some time since 1971 were
excluded. Finally, 1.6% of patients were excluded because their
vital status was unknown on 5 November 2002, when the data were
extracted for analysis. In all, more than 141 500 patients were
included in the analyses (88% of those eligible).
SURVIVAL TRENDS
For bladder cancer patients diagnosed during 1996–1999, relative
survival at 1 year was 82 and 71% for men and women,
respectively, and 67 and 56% at 5 years (Table 1, Figure 1).
Survival barely changed at all between the late 1980s and the late
1990s: deprivation-adjusted trends were very close to zero. Ten-
year survival for patients diagnosed in the early 1990s was 60% for
men and 54% for women.
The most striking feature is the persistent 6– 10% survival
advantage for men at 1, 5 and 10 years after diagnosis.
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Examination of patients’ survival experience during 2000–2001
with hybrid analysis (Brenner and Rachet, 2004) does not suggest
that survival up to 10 years after diagnosis is likely to increase in
the near future (Table 1).
DEPRIVATION
The deprivation gap in survival at 1, 5 and 10 years between the most
affluent and the most deprived groups ranged from 4 to 10%.
This was remarkably consistent for both men and women
diagnosed from the late 1980s to the late 1990s. All the estimates
of the deprivation gap in survival were statistically significant at
the 1% level (Table 2, Figure 2).
The deprivation gap in survival up to 10 years widened slightly
for both sexes, but the rate of change every 5 years was not itself
statistically significant.
Hybrid analysis does not suggest any imminent change in the
deprivation gap in survival up to 10 years for men, although some
reduction of the socioeconomic differences may occur for women
(Table 2).
COMMENT
Survival for bladder cancer patients diagnosed in England and
Wales during 1996–1999 seems to have been no higher than for
patients diagnosed during 1986–1990, a decade earlier. Since
survival up to 5 years did not increase by more than 2–3%
between the early 1980s and the late 1980s either (Coleman et al,
1999), it would seem that bladder cancer survival in England and
Wales as a whole has not increased much for almost 20 years.
The large and significant deprivation gap in survival between the
most affluent and deprived patients (4 to 10%) has not shrunk
either.
The male survival advantage for bladder cancer (6–10%) is
larger than for cancers of the upper urinary tract (2–4%). This has
been a consistent feature for both cancers since the 1970s
(Coleman et al, 1999). It is all the more striking because among
the other common cancers, only breast cancer shows a survival
advantage for men.
Changes in the spectrum of what is recorded – and treated – as
an invasive malignant tumour can affect the interpretation of time
trends in population-based cancer incidence and survival. Trends
are more difficult to interpret for bladder cancer than for many
other cancers, because of difficulties in the pathological definition
of disease, variation between cancer registries in coding practice,
and changes over time in both factors. Thus, the proportion of
bladder tumours coded as in situ or of uncertain behaviour in
England and Wales jumped from virtually zero for 1986– 1990 to
an average of 23% for 1996–1999. Similarly, the proportion of
in situ tumours rose from 1 to 7% in the United States during the
1970s and has continued to rise since then (Silverman et al, 2006).
Small biopsy fragments taken at cystoscopy may not enable the
pathologist to determine unequivocally if the tumour is invasive or
in situ, but the speed and magnitude of this shift must reflect
changes in the pathological classification and registry coding of
bladder tumours more than true change in the pathology of
disease.
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 82.2 (81.7, 82.6) 82.7 (82.3, 83.1) 81.6 (81.1, 82.1) 0.0 (0.9, 0.9) 81.4 (80.6, 82.1)
Women 72.2 (71.4, 73.0) 71.2 (70.4, 72.0) 70.6 (69.7, 71.5) 0.2 (1.5, 1.9) 71.1 (69.8, 72.4)
5 years Men 66.3 (65.7, 67.0) 66.6 (66.0, 67.2) 66.5 (65.6, 67.4) 0.7 (0.7, 2.2) 66.1 (65.1, 67.2)
Women 58.7 (57.7, 59.8) 58.0 (57.1, 59.0) 56.3 (55.0, 57.6) 0.8 (3.0, 1.5) 57.0 (55.4, 58.6)
10 years Men 59.1 (58.3, 59.9) 60.3 (59.4, 61.3) 2.7 (0.7, 6.0) 60.9 (59.6, 62.2)
Women 53.6 (52.4, 54.8) 53.9 (52.6, 55.2) 3.6 (1.2, 8.3) 53.0 (51.2, 54.9)
CI=confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008).
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated
with cohort or complete approach (1986–1990, 1991–1995, 1996–
1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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The declining incidence of invasive cancer of the bladder
probably reflects earlier declines in tobacco smoking, but it may
also echo this shift in the recorded spectrum of malignant
behaviour. An increasing proportion of bladder tumours is now
being coded as in situ or uncertain if benign or malignant. Some of
these tumours are of low invasive potential (Newling et al, 1995).
The recommended change in coding practice by European
registries was made in 1995, but pathological practice may have
changed before that. If a substantial proportion of bladder
tumours that were classified by the pathologist (and coded by
the cancer registry) as invasive during the 1980s would have been
coded as in situ or of uncertain malignancy in the late 1990s, this
would tend to cause both a decline in the recorded incidence of
invasive cancer of the bladder and – as those low-grade tumours
would also be excluded from survival analysis – a decline in
survival from bladder cancer.
Regional variation within England and Wales in the percentage
of bladder tumours coded as in situ or of uncertain malignancy
is very wide. The overall percentage of in situ tumours during
1986– 1999 ranged from less than 1 up to 27% among the 10 cancer
registries (national average 8.1%). In some registries, it rose from
less than 1% in 1986–1990 to 35% by 1996– 1999, whereas in
others it was stable at 1 –2% (data not shown). A similar pattern
was seen for tumours of benign or uncertain behaviour, the
percentage ranging from 0.4 to 31% of all bladder tumour
registrations during the period 1986– 1999 (national average
3.4%), with similarly disparate trends among registries over that
period. This must overstate any true underlying regional variation,
and it reflects differences in pathological classification and registry
coding practice. The relevance of these patterns is that the national
data for the period 1986– 1999 do not comprise a consistently
defined group of bladder cancers.
Thus, a study of 1500 bladder cancer patients diagnosed in the
West Midlands in 1990–1991 (Begum et al, 2004) found a
socioeconomic gradient in crude (all-cause) survival, but not in
cause-specific survival (deaths certified as due to bladder cancer),
which should be very close to relative survival if death certification
is accurate. The difference in crude survival at 5 years between
the most affluent and most deprived groups (7%) was similar to
that seen for West Midlands and for England as a whole during
1986– 1990 (Coleman et al, 1999), but the survival estimates
themselves (56–63%) were some 15% higher. These discrepancies
suggest both errors in attribution of the cause of death and/or
selection bias: fewer tumours were classified as in situ or benign in
the West Midlands during 1986–1999 than in other regions of
England (data not shown).
Bladder cancer survival rates observed in the late 1990s may
therefore reflect a more aggressive spectrum of bladder tumours
than those retained in survival analyses for the 1980s. This might
help to explain why survival from bladder cancer seems to have
improved so little between the 1980s and the 1990s.
More robustly interpretable information on population-
based bladder cancer survival trends will require greater
consistency in pathological definition and coding than seems
to be available at present; this will take some time. In the
meantime, examination of survival trends by stage of disease at
diagnosis should prove informative, particularly if early-stage
disease were excluded.
50
60
70
80
90
5-
ye
ar
 re
la
tiv
e 
su
rv
iva
l (%
)
Affluent 2 3 4 Deprived
Deprivation category
Men
40
50
60
70
80
5-
ye
ar
 re
la
tiv
e 
su
rv
iva
l (%
)
Affluent 2 3 4 Deprived
Deprivation category
2000– 2001
1996–1999
1991–1995
1986–1990
Women
Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
sex and calendar period of diagnosis: England and Wales, adults (15–99
years) diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986 –1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men 4.1** (5.5, 2.8) 5.3** (6.6, 4.1) 4.6** (6.1, 3.1) 0.3 (1.4, 0.7) 4.8** (6.9, 2.6)
Women 4.3** (6.8, 1.9) 7.0** (9.4, 4.7) 6.5** (9.2, 3.8) 1.2 (3.1, 0.7) 5.3** (9.2, 1.5)
5 years Men 4.4** (6.3, 2.4) 6.5** (8.4, 4.7) 5.7** (8.2, 3.1) 0.9 (2.5, 0.8) 6.1** (9.1, 3.0)
Women 5.3** (8.3, 2.3) 9.7** (12.5, 6.8) 5.8** (9.5, 2.0) 0.7 (3.2, 1.8) 3.4 (8.1, 1.4)
10 years Men 3.8** (6.2, 1.3) 5.9** (8.8, 3.1) 2.2 (5.9, 1.5) 6.5** (10.2, 2.8)
Women 6.0** (9.6, 2.5) 10.2** (14.1, 6.2) 4.1 (9.4, 1.2) 2.5 (8.0, 3.1)
CI=confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in the deprivation gap in survival every 5 years,
adjusted for the underlying trend in survival (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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The shift since the mid-1990s towards a more malignant
spectrum of bladder tumours that have been classified and
coded as invasive in most registries may partly explain the
overall lack of improvement in bladder cancer survival in
England and Wales, but it does not explain why the wide
socioeconomic inequalities in survival have not been reduced;
nor does it explain the persistent sex difference in survival from
bladder cancer.
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